Connor Iapoce

Increases in oxidized HDL levels were linked to HFpEF in new analyses, suggesting reduced antioxidant HDL function is present in this patient population.

The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 18, 2025.

With a completed 12-week analysis, Outlook Therapeutics plans to resubmit the Biologics License Application for ONS-5010 in the first quarter of 2025.

Semaglutide 7.2 mg achieved statistically significant and superior weight loss at 72 weeks versus placebo, hitting the Phase 3b trial's primary endpoint.

Medicare has selected 15 additional drugs to negotiate prices directly with participating drug companies, including semaglutide (Ozempic).

Axatilimab in 9 mg and 22 mg vial sizes are expected to launch in early February for the treatment of chronic graft-versus-host disease.

With a Phase 3 trial expected in 2025, linsitinib is the first oral small-molecule therapy to demonstrate statistical significance in thyroid eye disease.

A cohort study with 14 years of follow-up found monogenic and polygenic mechanisms influencing LDL-C and incident T2D risk inversely associated.

Samsara Vision announced the implantable miniature telescope improved distance and near vision 6 months post-surgery for patients with late-stage AMD.

An infusion of ferric carboxymaltose in the third trimester significantly reduced anemia in pregnant women, surpassing the efficacy of iron tablets.

All participants with RP treated with OCU400 gene therapy achieved vision improvement or preservation at 2 years of the Phase 1/2 trial.

A new study highlights notable obesity-associated disruptions of iron metabolism, with higher hemoglobin and serum ferritin levels in pre-obese and obese cohorts.

Nearly half of patients with acute coronary syndrome in a single-center analysis exhibited iron deficiency, with anemia linked to a greater impact on mortality.

Aspirin avoidance remained safe and did not increase thrombosis risk after LVAD implantation in patients with a history of atherosclerotic vascular conditions.

Atumelnant rapidly lowered key biomarkers in congenital adrenal hyperplasia in positive topline results from the Phase 2 TouCAHn trial.

Submission of the supplemental NDA was based on positive findings from the FINEARTS-HF trial investigating finerenone for heart failure with an LVEF ≥40%.

4D-150 shows promising efficacy and safety in DME as FDA greenlights Phase 3 trial for Biologics License Application submission.

Aflibercept 8 mg achieves non-inferior vision gains with an every 8-week dosing interval in patients with macular edema following retina vein occlusion.

Additional TEASE-3 participants who completed 24 months of gildeuretinol therapy reported no progression in Stargardt disease, including stable visual acuity.

After accepting the avacincaptad pegol sNDA on January 6, 2025, the FDA has set a target action date for February 26.

An economic analysis highlights a cardiovascular polypill's potential to lower healthcare costs and address income-based health disparities.

Hyperuricemia was significantly linked to dyslipidemia and hypertriglyceridemia in hospitalized patients with type 2 diabetes, which remained after adjustment.

Variations in apoB concentration among Hispanic or Latino populations could provide important implications for apoB use in cardiovascular risk assessment.

OCS-05 meets primary safety endpoints and demonstrates a neuroprotective structural benefit, as well as visual improvement, in topline results from ACUITY.

Our Endocrinology Month in Review for December 2024 highlights recent headlines in diabetes and endocrinology and 4 new episodes of Diabetes Dialogue.

Higher levels of small-particle HDL were linked with greater gray matter volume and higher cognitive capacity among middle-aged adults.

A systematic review and meta-analysis of observational real-world data finds nearly half of patients who begin a GLP-1 RA will discontinue within a year.

Potassium nitrate increased blood nitric oxide metabolites but showed no improvement in exercise tolerance or quality of life in a population with HFpEF.

A look back at some of our top coverage in ophthalmology from 2024, including pipeline news and FDA approvals.

From groundbreaking therapies to ethical dilemmas, HCPLive’s top podcasts of 2024 delivered expert insights and human stories across medicine.